Clinical Cancer Research APC and Open Access: AACR's Translational Bridge at Moderate Cost

These two journals are often confused, and the distinction matters for where your paper fits:

Clinical Cancer Research occupies a specific niche: it wants work that connects laboratory findings to patient outcomes. The ideal paper includes both molecular data and clinical validation. A biomarker discovery study that shows prognostic value in a patient cohort fits perfectly. The same biomarker study without clinical validation belongs in Cancer Research or a molecular biology journal.

The journal is particularly strong in:

• Biomarker development and validation

• Correlative science from clinical trials (the molecular analyses that accompany phase I-III studies)

• Pharmacodynamic and pharmacokinetic studies of cancer therapeutics

• Imaging biomarkers and diagnostic development

• Immunotherapy response prediction and resistance mechanisms

Clinical Cancer Research is hybrid:

1. Copyright-transfer (subscription) track, no APC: Published behind the AACR paywall. Institutional subscribers have access. You pay the $2,700 base publication fee plus $250 per figure or table.

1. Gold OA track ($7,000 or $8,000): Immediate free access under a CC BY-NC-ND or CC BY license. You pay the flat APC instead of the base and display item fees.

The subscriber base for AACR journals covers virtually every academic medical center and cancer research institution. Oncologists and translational researchers at these institutions can access Clinical Cancer Research through their library subscriptions. Behind the paywall, your paper still reaches the people who need to read it.

OA becomes more valuable for Clinical Cancer Research than for some basic science journals because of its clinical audience. Community oncologists, clinical trial coordinators at smaller sites, and researchers in lower-resource settings may not have institutional subscriptions. If your work has direct clinical practice implications, OA broadens its reach to these groups.

AACR membership affects the fees on the copyright-transfer route, not the open access fee:

• Member discount: If any bylined author is an Active AACR member, AACR applies a 10% discount on the total charges, excluding any open access fee.

• Submission fee: The $40 manuscript submission fee is not required if one bylined author is an Active AACR member in good standing and has validated their member number in SmartSubmit.

• No OA discount: AACR states that its member, editor, grantee and country discounts exclude the open access fee at its hybrid journals.

If you plan to publish under copyright transfer, an Active AACR member among the authors lowers the cost and removes the submission fee. If you plan to publish open access, membership does not change the $7,000 or $8,000 APC.

AACR applies the same discount framework across its journals:

• Country-specific discounts: AACR gives a 25%, 50% or 100% discount on the total charges, excluding any open access fee, based on the location of the corresponding author's primary affiliation. AACR sets the country classification using R&D funding per capita and cancer funding, and does not provide these discounts for work principally conducted for a commercial organization.

• Waiver requests: Under exceptional circumstances, when no grant or other source of support exists, authors may apply at the time of submission for a partial or full waiver of the standard publication fee. The application must be countersigned by an appropriate institutional official.

• Open access fee: The country-specific discounts and waivers do not apply to the open access fee at AACR's hybrid journals.

Clinical Cancer Research papers often come from large, funded clinical trials with substantial budgets. For these, APC funding is rarely an issue. The waiver system is more relevant for investigator-initiated translational studies from labs with tighter budgets, particularly at institutions outside major cancer centers.

For articles published open access, AACR deposits the version of record in PMC and Europe PMC automatically, with no embargo. For NIH-funded work accepted on or after July 1, 2025 and published under standard copyright transfer, the Author Accepted Manuscript can be made public in PMC on or after the first online publication of the version of record. AACR deposits it on request only when the corresponding author is an Active AACR member, and all other authors must self-deposit.

For Plan S funders, check your funder's license requirement before you choose. Clinical Cancer Research offers open access under CC BY-NC-ND or CC BY.

Beyond the listed APC, watch for:

• Publication fees under copyright transfer: AACR charges a $2,700 base fee plus $250 per figure or table, so a paper with 6 display items pays $4,200 before discounts. Many authors are surprised by this invoice.

• Statistical review requests: Clinical Cancer Research may require statistical review or reanalysis during revision. If your institution charges for biostatistics consulting, budget for this.

• Clinical data formatting: The journal asks reports of randomized trials to follow the CONSORT guidelines, which can add figure work. Professional figure preparation may cost $200-$500 if your team doesn't have the tools in-house.

• Submission fee: AACR charges a nonrefundable $40 processing fee at initial submission of original research from February 17, 2026, unless a bylined author is an Active AACR member who has validated their member number in SmartSubmit.

• Companion diagnostics data: Papers on biomarker-driven therapy often need supplementary validation datasets. Depositing large genomic datasets in GEO or EGA is free but time-consuming.

AACR reports timing for all of its journals together, not for Clinical Cancer Research alone. For submissions in 2024, the median first decision after peer review was 35 days, and the median first decision without peer review (triage or desk rejection) was 3.8 days.

AACR does not publish a desk-rejection rate. Papers that are clearly outside the translational scope (pure basic biology or pure clinical reporting without molecular correlates) get redirected quickly. The editors want to see both a molecular story and clinical relevance.

For translational oncology researchers considering Clinical Cancer Research:

1. Check whether an author is an Active AACR member. Membership gives a 10% discount on the base publication and display item fees and removes the $40 submission fee. It does not reduce the open access fee.

1. Compare the two routes. Copyright transfer costs a $2,700 base fee plus $250 per figure or table. Open access is a flat $7,000 (CC BY-NC-ND) or $8,000 (CC BY).

1. Ask your library about institutional deals. AACR's fee and open access pages do not describe any, so confirm before you assume the APC is covered.

1. NIH/NCI-funded? For articles accepted on or after July 1, 2025, the Author Accepted Manuscript can go into PMC on or after first online publication. AACR deposits it for you only on request from an Active AACR member who is the corresponding author. You still pay the copyright-transfer fees.

1. Choosing between CCR and JCO? If your paper has strong molecular biomarker data driving clinical conclusions, CCR is the natural home. If it's a clinical trial report, JCO or Annals of Oncology is more appropriate.

Translational manuscripts need to tell a coherent story from bench to bedside. The molecular data and the clinical data have to connect logically, and the framing needs to show why the translational finding matters for patient care. Clinical Cancer Research submission readiness check to check whether your manuscript's translational narrative holds together before you submit.

For the latest fee schedule and author guidelines, visit the AACR publication fees page and the Clinical Cancer Research author information page.

Worth paying if:

• Your funder mandates open access (check Plan S / cOAlition S requirements)

• An institutional Read & Publish agreement covers the fee

• Open access visibility meaningfully benefits your research area

• The APC fits within your grant budget

Consider alternatives if:

• The APC is a personal out-of-pocket expense

• A subscription option or green OA (preprint + embargo) satisfies your funder

• Another OA journal with a lower APC would provide similar visibility

For a manuscript-specific signal before you submit, run a Clinical Cancer Research submission readiness check.

Or see example reports before you finalize.